ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

Post author:Marianne Duparc
Post published:February 8, 2022
Post category:Newsroom

ERYTECH Pharma announced the allowance of a US patent application covering arginine deiminase (ADI) encapsulated into red blood cells for the treatment of arginase-1 deficiency (A1D), a debilitating rare metabolic disease

You Might Also Like

ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI

ERYTECH receives the EnterNext Tech 40 Label

ERYTECH to Present at the H.C. Wainwright Global Investment Conference